1,089,119 Veradermics, Incorporated $MANE Shares Sold by Aberdeen Group plc

Veradermics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group cut its Veradermics stake by 99.3%, selling 1,089,119 shares in the third quarter and retaining 7,523 shares valued at $912,000.
  • Analysts have a “Moderate Buy” consensus on MANE, with an average price target of $174.57; seven analysts rate it Buy, one Hold, and one Sell.
  • Veradermics reported a quarterly loss of $0.50 per share, narrower than the $0.59 loss analysts expected. Separately, major shareholder Longitude Capital sold 500,000 shares for about $75.2 million.
  • MarketBeat previews top five stocks to own in December.

Aberdeen Group plc cut its position in Veradermics, Incorporated (NYSE:MANE - Free Report) by 99.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,523 shares of the company's stock after selling 1,089,119 shares during the quarter. Aberdeen Group plc's holdings in Veradermics were worth $912,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MANE. Montanova Capital LLC bought a new stake in Veradermics in the second quarter valued at approximately $512,533,000. Bamco Inc. NY raised its stake in Veradermics by 284.8% in the 2nd quarter. Bamco Inc. NY now owns 229,581 shares of the company's stock valued at $28,225,000 after acquiring an additional 169,913 shares during the period. Seven Fleet Capital Management LP bought a new stake in Veradermics in the 2nd quarter valued at $9,835,000. Wellington Management Group LLP acquired a new stake in Veradermics during the 2nd quarter valued at $8,425,000. Finally, Alps Advisors Inc. lifted its holdings in Veradermics by 31.2% during the 3rd quarter. Alps Advisors Inc. now owns 55,356 shares of the company's stock valued at $6,711,000 after purchasing an additional 13,150 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on MANE shares. B. Riley Financial upped their price target on shares of Veradermics from $170.00 to $204.00 and gave the company a "buy" rating in a research note on Thursday, October 22nd. Needham & Company LLC upped their target price on Veradermics from $164.00 to $172.00 and gave the company a "buy" rating in a research report on Monday, October 19th. UBS Group set a $204.00 target price on Veradermics in a research note on Thursday, October 22nd. Citigroup boosted their price target on Veradermics from $160.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, November 10th. Finally, Wall Street Zen raised Veradermics from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $174.57.

Read Our Latest Analysis on MANE

Veradermics Stock Performance

MANE opened at $119.39 on Friday. Veradermics, Incorporated has a 52-week low of $32.00 and a 52-week high of $156.63. The firm has a market cap of $5.04 billion and a P/E ratio of -49.75. The business's fifty day moving average is $124.64 and its 200-day moving average is $99.06.

Veradermics (NYSE:MANE - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. On average, research analysts predict that Veradermics, Incorporated will post -2.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Veradermics news, major shareholder Longitude Capital Partners V, sold 500,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $150.38, for a total value of $75,190,000.00. Following the sale, the insider owned 1,803,474 shares in the company, valued at $271,206,420.12. This trade represents a 21.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link.

Veradermics Company Profile

(Free Report)

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

See Also

Institutional Ownership by Quarter for Veradermics (NYSE:MANE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Veradermics Right Now?

Before you consider Veradermics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradermics wasn't on the list.

While Veradermics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines